TrialBMC cancer2018

A phase II trial of recombinant MAGE-A3 protein with immunostimulant AS15 in combination with high-dose Interleukin-2 (HDIL2) induction therapy in metastatic melanoma.

Jennifer L McQuade et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.